The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XIII. Esophageal involvement

XIII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

XIII. Esophageal involvement

XIII.d Esophageal toxicity

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.e Pulmonary hematoma

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.k Epistaxis

IV. Airway involvement

IV.ah Calcification of tracheobronchial cartilaginous rings

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.b Hematoma of/around central airway wall potentially causing UAO

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.r Tongue involvement (edema, glossitis, hematoma)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.u Vocal cord hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.v Retropharyngeal hematoma (may cause UAO)

VI. Pleural and/or pericardial involvement

VI.e Hemothorax - Serosanguineous pleural effusion

VI. Pleural and/or pericardial involvement

VI.n Hemopericardium - Bloody pericardial effusion

VIII. Mediastinal involvement

VIII.g Hemomediastinum - Mediastinal hematoma

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.x Thoracic epidural or spinal hematoma

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

XI. Miscellaneous

XI.i Esophageal hematoma (may cause chest pain and/or tracheal compression)

XI. Miscellaneous

XI.aj Rectus abdominis hematoma

XII. Cardiovascular involvement / toxicity

XII.at Calcification of the coronary artery walls or atheroma

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.d BAL: Gross or microscopic bleeding/hemorrhage

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.e BAL: Stainable iron in macrophages

XXVI. Veterinary medicine

XXVI.h Veterinary: Tracheal hemorrhage, stenosis, collapse

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ap Pulmonary infiltrates

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.h Major/massive hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.l Alveolar hemorrhage, localized (e.g. lobar)

IV. Airway involvement

IV.n Bronchial wall erosion/hematoma

IV. Airway involvement

IV.ab Cough (lone)

IV. Airway involvement

IV.ak Bronchopericardial fistula

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.b Hematoma of/around central airway wall potentially causing UAO

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.d Laryngeal disorder-Laryngeal nerve palsy (dysphonia, hoarseness)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.f Vocal cord dysfunction, adduction, closure, injury

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.e Hemothorax - Serosanguineous pleural effusion

VI. Pleural and/or pericardial involvement

VI.n Hemopericardium - Bloody pericardial effusion

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.o Air/gas embolism

VII. Pulmonary vasculopathy

VII.y Pulmonary vein stenosis

VII. Pulmonary vasculopathy

VII.ab Pulmonary infarction

VII. Pulmonary vasculopathy

VII.ad Pulmonary vein perforation/rupture

VIII. Mediastinal involvement

VIII.d Fibrosing mediastinitis

VIII. Mediastinal involvement

VIII.g Hemomediastinum - Mediastinal hematoma

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.n Vagal nerve injury (may cause GE reflux/GERD)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.i Esophageal hematoma (may cause chest pain and/or tracheal compression)

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.aa Pneumopericardium

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.ay Postcardiac/-cardiotomy injury (PCIS-Dressler syndrome)

XII. Cardiovascular involvement / toxicity

XII.bg Perforation of the heart - Cardiac rupture

XII. Cardiovascular involvement / toxicity

XII.bj Atrio-esophageal fistula

XII. Cardiovascular involvement / toxicity

XII.bk Atrial septal defect, acquired

XII. Cardiovascular involvement / toxicity

XII.bn Pulmonary vein thrombosis

XII. Cardiovascular involvement / toxicity

XII.bz Pericardial-esophageal fistula

XIII. Esophageal involvement

XIII.b Esophageal pathology (erosion, ulcer, tear, rupture, fistula)

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XVI. Imaging

XVI.l Imaging: Peribronchovascular areas of consolidation

XVI. Imaging

XVI.bi Imaging: Pulmonary vein stenosis

XVI. Imaging

XVI.br Imaging: Localized calcification of pulmonary vein or veins

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.s Path: Pulmonary congestion

XIX. Pathology

XIX.bd Path: Pulmonary veno-occlusive disease (PVOD)

XIX. Pathology

XIX.da Path: Pulmonary vein stenosis

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.i Subclinical pulmonary infiltrates/ILD

I. Interstitial/parenchymal lung disease

I.l Lung nodule or nodules

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.y Pleuroparenchymal fibroelastosis (PPFE)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.av The chemotherapy lung

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

II. Pulmonary edema - Acute lung injury - ARDS

II.f ARDS and the hemolytic-uremic syndrome (HUS)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.j Bronchiectasis

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.c Pulmonary veno-occlusive disease

VII. Pulmonary vasculopathy

VII.f Hemolytic and uremic syndrome (HUS). See also under Xaf

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.j Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.p Tumor lysis syndrome (TLS)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.t Cavitation/necrosis of lung tumor or metastases

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.b Valvular heart disease and/or dysfunction

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.m Atrial fibrillation

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XVI. Imaging

XVI.ac Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp)

XVI. Imaging

XVI.ad Imaging: Lung cysts or bullae (see also XVI ah/bf)

XVI. Imaging

XVI.bh Imaging: Tumoral cavitation

XVI. Imaging

XVI.bp Imaging: An area or areas of avid tracer uptake in the lung/chest on 18F-PET scan

XVI. Imaging

XVI.by Imaging: Air or an air crescent around lung tumor or metastase(s)

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.g BAL: Atypical epithelial cells (at times poetically named

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.q Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XIX. Pathology

XIX.ba Path: Thrombosis in pulmonary arterioles/venules

XIX. Pathology

XIX.bd Path: Pulmonary veno-occlusive disease (PVOD)

XIX. Pathology

XIX.bx Path: Granulomatous lymphadenopathy

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

XX. Infections & related conditions

XX.r Fungal infection (pulmonary/extrapulmonary)

XX. Infections & related conditions

XX.ae Reactivation of a prior pulmonary infection (TB, melioidosis)

XXI. Neoplastic conditions

XXI.a Lung cancer

XXI. Neoplastic conditions

XXI.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XXI. Neoplastic conditions

XXI.d Malignant mesothelioma (pleural, pericardial)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.k Tracheal narrowing - Sabre sheath trachea

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.e Fat/oil embolism - The FES embolism syndrome

VII. Pulmonary vasculopathy

VII.ac Right ventricular outflow tract compression

VIII. Mediastinal involvement

VIII.c Mediastinal lipomatosis

VIII. Mediastinal involvement

VIII.g Hemomediastinum - Mediastinal hematoma

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

VIII. Mediastinal involvement

VIII.j Compression of mediastinal structures/organs

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.f Hiccup

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.m Epidural thoracic lipomatosis

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.p Disordered breathing during sleep - Sleep apnea

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.v Generalized myopathy/muscle weakness

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.p Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.au Scleroderma renal crisis

X. Systemic/Distant conditions, syndromes and reactions

X.bb Rhabdomyolysis (see also under Xj)

XI. Miscellaneous

XI.s Rib fracture

XI. Miscellaneous

XI.ad Vertebral compression fracture

XI. Miscellaneous

XI.af Cushing syndrome

XI. Miscellaneous

XI.aq Diminished efficacy of antineoplastic immunotherapy

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.x Hypertrophic cardiomyopathy

XVI. Imaging

XVI.av Imaging: Subpleural fat deposits

XVI. Imaging

XVI.aw Imaging: Mediastinal fatty deposits

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.d Pneumocystis jiroveci pulmonary colonization

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.j Mucormycosis (pulmonary, tracheobronchial or systemic)

XX. Infections & related conditions

XX.m Fungal airway infection

XX. Infections & related conditions

XX.o Nocardia pulmonary/systemic infection

XX. Infections & related conditions

XX.r Fungal infection (pulmonary/extrapulmonary)

XX. Infections & related conditions

XX.u Strongyloides stercoralis hyperinfection (w/wo DAH)

XX. Infections & related conditions

XX.v Hypogammaglobulinemia - Antibody deficiency

XX. Infections & related conditions

XX.ah A falsely negative/indeterminate IGRA test result

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.c Pleural thickening - Fibrothorax

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.h Chylothorax

VI. Pleural and/or pericardial involvement

VI.i Pleuritis (can cause chest pain)

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.t Fluid retention

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XVI. Imaging

XVI.m Imaging: Interlobular septal thickening

XVI. Imaging

XVI.ap Imaging: Pleural effusion

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.n Path: Pulmonary alveolar proteinosis pattern (PAP pattern)

XIX. Pathology

XIX.bm Path: Pleuritis, pleural fibrosis

XIX. Pathology

XIX.bp Path: Organizing fibrinous pleuritis (OFP)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.r Pulmonary nodulosis

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.d Pulmonary vasculitis or capillaritis

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.q Obstructive sleep apnea

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.at Relapse/flare/onset of Crohn's disease

XI. Miscellaneous

XI.aa Granulomas on tattoo edges

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.bx Path: Granulomatous lymphadenopathy

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.f Tuberculosis, miliary

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XX. Infections & related conditions

XX.aa Protozoan infection (incl. leishmaniasis)